Early onset of cardiometabolic risk factor profiles in drug naïve adolescents and young adults with first-episode schizophrenia
Section snippets
Role of funding source
This work was supported by Natural Science Training Project by Xinxiang Medical University 2013ZD107 (to DZ), Program for Science&Technology Innovation Talents in Universities of Henan Province, China 14HASTIT034 (to YZ) and Undergraduate Innovation Project by Ministry of Education of China 201310472020, 201310472003, 201310472011. Partly supported by the support project for the Disciplinary Group of Psychology and Neuroscience, Xinxiang Medical University 2016PN-KFKT-30 (to YZ).
Contributors
YZ, DZ and YL designed studies, performed the experiments, wrote manuscript. RZ designed studies and contributed to revising manuscript. YF, YL, TC, CN, GD, YJ, XZ performed the experiments and contributed to revise manuscript. YC and XW contributed to revise manuscript. All authors participated in revising the manuscript and the final approval of the manuscript.
Conflict of interest
All other authors declare that they have no conflicts of interest.
Acknowledgements
The authors thank Dr. Dost Öngür (Harvard Medical School, McLean Hospital) for his suggestions on study concept and design. The authors also thank MD. Tuna Hasoglu (McLean Hospital) revised the language of the manuscript.
References (7)
- et al.
The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis
Lancet Psychiatry
(2016) - et al.
Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment
Schizophr. Res.
(2017) - et al.
Prevalence of metabolic syndrome in female and male patients at risk of psychosis
Schizophr. Res.
(2016)
Cited by (14)
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients
2020, European NeuropsychopharmacologyCitation Excerpt :Furthermore, our results suggest that if the weight gain is controlled, we can reduce lipid and glycaemic abnormalities secondarily due to his correlation. Despite of this, recent studies have proposed that cardiometabolic risk factors and other metabolic abnormalities are present early in the illness (Pillinger et al., 2017; Zhai et al., 2017; Correl et al., 2014), even regardless of antipsychotic exposure (Pillinger et al., 2017; Jensen et al., 2017). These evidences suggest that the metabolic alterations seen in psychosis have a multi-factor etiology, including not only the effect of antipsychotic treatment but also many other clinical, sociodemographic and environmental elements, such as sedentary lifestyle and eating habits.
Benefits and Meaning of Lipids Profile in Relation to Oxidative Balance and Brain Morphology in Schizophrenia
2023, International Journal of Molecular SciencesEvidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia
2021, Journal of Psychopharmacology
- 1
Both authors contributed equally to this work.